10-K / 10-Q
Annual (10-K) and quarterly (10-Q) SEC filings providing comprehensive financial statements, risk factors, and management discussion for public companies.
Definition
The 10-K and 10-Q are mandatory SEC filings that form the backbone of public company financial disclosure. The 10-K is the comprehensive annual report filed within 60 days of fiscal year-end for large accelerated filers, containing audited financial statements, management discussion and analysis (MD&A), risk factors, and detailed business descriptions. The 10-Q covers the same ground quarterly but with unaudited financials and condensed disclosure.
While earnings calls get the headlines, the 10-K and 10-Q are the documents that institutional analysts actually model from. Every revenue breakdown, segment disclosure, risk factor update, and accounting policy footnote feeds directly into the financial models that drive buy and sell decisions. The language in the MD&A section sets the narrative framework that analysts use when writing research reports.
Why It Matters
Sell-side analysts build their financial models primarily from 10-K and 10-Q data. The granularity of segment reporting, the specificity of risk factor disclosures, and the tone of management discussion directly influence how the investment community models future earnings and assesses risk. Vague or boilerplate disclosure invites uncertainty, which typically translates to a discount in valuation multiples.
Companies that approach their periodic filings as investor communication opportunities — with clear MD&A narratives, meaningful segment breakdowns, and thoughtfully updated risk factors — give analysts the information needed to model the business accurately. This reduces the gap between management expectations and consensus estimates, leading to fewer earnings surprises and more stable stock performance.
Examples in Practice
A SaaS company revamps its 10-K segment disclosure to separately break out its fastest-growing product line. Analysts immediately update their models to value the high-growth segment at a premium multiple, contributing to a 15% increase in the average price target within two quarters.
A healthcare company updates its 10-Q risk factors to transparently address a pending FDA decision, including multiple scenario outcomes. When the decision arrives unfavorably, the stock decline is muted because investors had already priced in the risk based on the disclosure.
A manufacturing company includes enhanced MD&A commentary on supply chain diversification progress in its 10-K, directly addressing the top investor concern from perception study results. The next quarter's non-deal roadshow conversations shift from supply chain risk to growth opportunities.